Summary: The quantitative determination of serum fentanyl (FT), urinary FT and its main metabolite, Nor-FT was examined to ascertain the individual variation in the elimination process of FT among 17 patients. The pharmacokinetics of FT was solved from the obtained data using 2-compartment model in cluding the metabolic process. Furthermore, we compared Nor-FT excretion with CYP3A4 activity based on urinary 6&beta;-hydroxycortisol (6&beta;-OHF) and cortisol (F) excretion ratio.<BR> FT and Nor-FT were determined by isotope dilution analysis using deuterium labeled FT (FT-<SUP>2</SUP>H<SUB>19</ or Nor-FT (Nor-FT-<SUP>2</SUP>H<SUB>10</SUB>) as internal standards. The isotopic fractionation was achieved by a capillary gas chromatograph equipped with a surface ionization detector. The pharmacokinetic parameters were calculat ed from serum FT concentration time profiles and excreted amount of FT and Nor-FT in urine, using the pharmacokinetic data analysis software, WinNonlin standard Ver. 1.5 (Scientific Consulting). Urinary F and 6&beta;-OHF concentrations were determined by HPLC using fludrocortisone as an internal standard after conversion to fluorescence derivative using 1,2-diamino-4,5-methylenedioxybenzene.<BR>
Introduction
Fentanyl [1-(2 phenethyl)-4-N-(N-propionylanili no) piperidine, FT] is a synthetic narcotic analgesic, it has a more effective and a shorter half-life than mor phine. It causes respiratory depression and its efficacy at tenuates rapidly'). Therefore, many pharmacokinetics studies have reported use of administration schedules of FT.
For the analysis of FT in plasma or serum, radioim munoassay (RIA)2,3), high-performance liquid chro matography (HPLC)4,6>, and gas chromatography (GC) 3,6,7) have been used. Several pharmacokinetic stu dies of FT have previously reported determinations us ing some of these methods, however, discordance of pharmacokinetic parameters between these reports has been reported8). Woestenborghs et a13). reported that the discordance was due to a lack of reproducibility of de termination limit, and an accurate assay method for these levels is necessary for study of the pharmacokinet ics of FT.
Isotope dilution analysis is precise and reproducible, because an isotope labeled compound is similar to the un 
Experimental
Collection of Serum and Urine Samples The subjects of the study (Table I) were 17 surgical patients, 12 women, and 5 men, ranging in age from 33 to 71 years. None of the patients had metabolic disease.
Informed consent was given by all patients, and the project was approved by the Research Committee of the Hospital. Anesthesia was induced by thiamylal (3 mg/kg) i.v. and vecuronium bromide (0.1 mg/kg) i.v. FT was ad ministered i.v. (5µg/kg) by a bolus injection as fentanyl citrate (Fentanest, Sankyo) for introduction of anesthe sia. Anesthesia was maintained by inhalation of isoflu rane or sevoflurane.
Blood samples were collected 12 times up to 3 hr after FT administration. These times were 0 (before adminis tration), 1, 6, 11, 16 ,21, 31, 61, 91, 121, 151 , and 181 min after administration. The blood was drawn from the cubitus vein and the collection volume was 3 ml. The in dwelling needle was Teflon coated and contained physio logical saline. The collected blood sample was trans ferred to an Insepack-S (Sekisui Medical) tube, kept at 37°C for 30 min, centrifuged for 3000 rpm/5 min, and the serum was separated. The serum (1.5 ml) was put into a silanized tube, capped, sealed with Parafilm, and refrigerated for 5-9 days at 4°C until analysis. Serum samples were prepared by the previously described extraction methods) with 1.5 ml of serum, to which was added 20 ng of FT-2H19 as an internal stan dard. The urine samples for FT were prepared by the previously described extraction method10 with 1 ml of urine, to which was added 20 ng of FT-2H19 as internal standard. Urine samples for Nor-FT were prepared by the previously described extraction and methyl deriva tion procedure10) with 1 ml of urine, to which was added 200 ng of Nor-FT-2H10 as an internal standard. The FT or Nor-FT concentration in each sample was calculated from the peak area ratio (FT or Nor-FT/IS) by capilla ry GC.
The GC system was equipped with a fused-silica capil lary column (25 m, 0.22 mm i.d.) with chemically bound ed methylpolysiloxane and a film thickness of 0.25 mm (Hicap-CBP1-M25-025, Shimadzu). A Shimadzu model GC-14A gas chromatograph equipped with a sur face ionization detector (SID) was used. The inlet sys tem used was solvent less of moving-needle type. The peak area was measured by a data processor, Shimadzu model C-R5A Chromatopac. The injection port was kept at 290°C, the column was operated at 180°C for Nor-FT or 260°C for FT and the detector temperature was 320°C. The carrier gas was helium at 1.4 ml/min. Differential equations concerning A, B, U, M, and C as serum concentration of FT can be converted to in tegral equations as described below by Laplace transfor mation.
f(ku-/3) (a-f) where a and /3 are defined as:
(k12+k21+k10+km) 2-4k21(k10+km) ) Pharmacokinetic parameters were obtained by the Gauss-Newton least squares method using the phar macokinetic data analysis software, WinNonlin standard Ver. 1.5 (Scientific Consulting). The serum concentra tion of FT (C), cumulative excretion amount of FT (LO, and cumulative excretion amount of Nor-FT (M) at each time were inputs. The initial value of each parameter was set to Ishii's value12), and the analysis range was set to 0-10 times Ishii's value. The other parameters, km, k12, A UC, A UMC, CL, MRT, Vdss, con clusive excretion amount of FT and Nor-FT, U and M°° were defined as shown below.
km= ( a kQ-k10 1 k12=a+f3-k21-k10 Evaluation of CYP3A4 Activity The urinary cortisol (F) and 6/3-hydroxycortisol (6,6 OHF) concentrations were determined by Inoue's method13) of HPLC determination using fludrocortisone as an internal standard after conversion to fluorescence derivative using 1,2-diamino-4,5-methylenedioxyben zene. The CYP3A4 activity was estimated by the 6,6 OHF/F molar concentration ratio in 1 ml of patient urine.
Statistics and Correlation
Significant difference was evaluated by the paired t test and the level of significance was chosen as p<0.05. The detection limit in this method were 4.5 pg (S/ N=3) for FT and 1.7 pg (S/N=3) for derivatized Nor FT (Nor-FT-Me) as the injection amount. For serum FT, the determination limit was 200 ng/ml and the reproducibility was 13A YO (RSD) in the same concentra tion. It is superior to previous methods using GC3,7) or HPLC4,5). For urinary FT, the determination limit was 400 pg/ml and the reproducibility was 16.7% (RSD) in the same concentration. For urinary Nor-FT, the deter mination limit was 10 ng/ml and the reproducibility was 4.0% (RSD) in the same concentration. The accuracy of these methods is adequate to determine for FT or Nor FT in urine.
Typical gas chromatograms of isotopic separation for serum FT are shown in Fig. 3 . No endogenous com pounds or concomitant drugs interfered with the detec tion of FT or FT-2H19. Serum concentration versus time profiles for FT in 17 patients are shown in Fig. 4 . The time of serum collection was limited to 180 minutes for dependence of the operation. There were individual differences in serum levels of FT grater than 10-fold. This variation was not associated with differences of pathology or operation technique. tion. In the patient with the highest serum FT, the cu mulative excretion amount of FT was the largest that over 10°/ of dose. Similarly, for cumulative excretion of Nor-FT, individual differences were observed as shown in Fig. 7 . No relationship between the cumulative excre tion amounts of FT and Nor-FT were observed. Previous studies have reported pharmacokinetics of FT being solved with 2-14-18) or 3-compartment models19-2s and 0.7-3.6% (FT). Thus, in our constructed model, the metabolic pathway of FT was assumed to be two routes that metabolize to Nor-FT and the others containing FT-p OH. Nor-FT was excreted to urine without further meta bolic exchange.
The pharmacokinetic parameters were solved with the 2-compartment model including the metabolic process using the time profiles of serum FT concentra tion and excretion amounts of FT and Nor-FT in urine. The predicted curve of time course for FT and Nor-FT was adapted to the FT kinetics as shown in Fig. 9 . Akai ke's an information criterion (AIC) from the parameters of each patient ranged from 40 to 159 (mean±SD, 82.5±32.2).
The mean values and standard deviations of phar macokinetic parameters are shown in Table II . The com parative table of pharmacokinetic parameters, together with that of a previous report, is shown in Table III . In this table, k10 is the elimination rate constant of FT to ex ternal that corresponds to the sum of k10 and km in our model. The parameters obtained from this study are not significantly different from those of previous reports.
There was a significant correlation between bleed volume and clearance (r=0.73). This correlation as sumed transition of FT to external by bleeding, but no correlation was found between pharmacokinetic parameters and other physical parameters such as age, height, weight, body mass index (BMI), and infusion volume. In Table II , the revealing considerable differ ences were noticed in k10, k21 and km between individ uals. The k10 was affected by renal function. It was reported that the clearance of FT was markedly decreased in patients with high blood urine nitrogen (BUN) concentration.29> But in this study, patients had no renal disease, the reason for k10 variation was not pronounced. The k21 was affected by the distribution of FT from peripheral to central. The back-flow of FT from skeletal muscle to blood by physical movement was reported19>. In this study, physical movement was not observed in anaesthesia because the patients was ad ministered muscle relaxant, vecuronium bromide.
The km was affected by metabolic process. In this study, the excretion rate (0/ of Dose) of Nor-FT up to 6 hr after administration was 7.1-50.2% (mean 17.2%), which was larger than the FT excretion rate (0.03 3.48%, mean 1.19%). In the case of our previous study28> by GC-MS analysis, urinary extraction of FT and Nor-FT were 0.7-3.6% and 8.2-25.2 0/ after con tinuous infusion FT (2-3 mg/body during 20-30 min), and 0.4-3.9% and 27.1-55.4% after bolus injection (0.5 mg/body). In this study too, the predicted final excre tion rates of FT and Nor-FT were 0.14-15.77% (mean 4.30%) and 7.36-99.38% (mean 55.12%) , respectively. These results indicated that dealkylation was the main route of FT metabolism. In this way, the pharmacokinetics of FT and Nor-FT are compatible with the 2-compertment model including the metabolic process, and Nor FT production has an influence on FT elimination. In a previous report, a drug metabolizing enzyme, CYP3A4, metabolized FT to Nor-FT30 33). The CYP3A4 activity is thought to be a dominant factor of FT pharmacokinetics in patients. We compared Nor-FT excretion with CYP3A4 activity esti mated from urinary 6$-hydroxycortisol (6/3-0HF) and cortisol (F) ratio by Inoue's method13>. We determined cortisol and 6$-hydroxycortisol in the urine before ope ration to avoid the affects of anesthesia. Urinary concen trations of F, 6fl-OHF, their ratio, and CYP3A4 activity in patients are shown in Table IV FT was reported34) to have a high hepatic extraction ratio (0.8). These results suggest that FT elimination was dominated by hepatic blood flow in preference to CYP3A4 activity. Palkama et al. reported35 ) that there were no significant difference in pharmacokinetics of FT using concomitant administration FT (3,ug/kg) with CYP3A4 inhibitor, itraconazole. For the same reason, CYP3A4 activity would not reflect FT elimination in our study which used a low dose of FT (5µg/kg).
In summary, the pharmacokinetics of FT and Nor-FT are compatible with a 2-compartment model including the metabolic processes, and the calculated parameters showed differences between individuals. The CYP3A4 activity from urine steroid was not reflected in FT elimi nation at low doses.
In a previous report, a reduction of hepatic blood flow was suggested in high-dose FT36). Further studies are needed to examine the individual variations in the elimi nation process of FT for high-dose anesthesia. 
